| Literature DB >> 34992861 |
Magdalena Łukowiak1,2, Grzegorz Galant3, Karolina Jezierska4, Michał Falco2, Piotr Woźniak1,2, Wojciech Podraza4, Janusz P Kowalski-Stankiewicz3.
Abstract
BACKGROUND: The present paper reports on analysis of 184 patients who were diagnosed with endometrial cancer. The main objective of this study was to address parameter Vrec(30Gy) which determines a volume of the rectum irradiated with a dose of 30 Gy during radiotherapy.Entities:
Keywords: endometrial neoplasms; medical physics; radiation oncology; radiotherapy; rectum
Year: 2021 PMID: 34992861 PMCID: PMC8726440 DOI: 10.5603/RPOR.a2021.0106
Source DB: PubMed Journal: Rep Pract Oncol Radiother ISSN: 1507-1367
Figure 1Clinical volumes: rectum volume in a target (Vrec(tar)) outlined in blue hatched area; total rectum volume (Vrec(tot)) outlined in green; planned target volume (VPTV) outlined in red
The Shapiro-Wilk test results for the data considered
| Parameter | p-value |
|---|---|
| Vrec(30Gy) (%) | < 0.01 |
| Vrec(tar) [cc] | < 0.01 |
| Vrec(tot) [cc] | < 0.01 |
| VPTV [cc] | 0.52 |
| Vrec(tar)/Vrec(tot) | < 0.01 |
Significance level = 0.05. Particular symbols denote: Vrec(30Gy) — rectum volume (in %) with 30 Gy dose, Vrec(tar) — rectum volume in a target, Vrec(tot) — total rectum volume, VPTV — planned target volume, Vrec(tar)/Vrec(tot) — ratio of the rectum volume in a target and total rectum volume.
significant results
Results of the Spearman correlation analysis
| Vrec(30Gy) | Vrec(tar) | Vrec(tot) | VPTV | Vrec(tar)/Vrec(tot) | ||
|---|---|---|---|---|---|---|
| Vrec(30Gy) | Spearman coeff. | – | −0.21 | −0.19 | 0.21 | 0.48 |
| p-value | – | < 0.01 | 0.01 | < 0.01 | < 0.01 | |
| Vrec(tar) | Spearman coeff. | 0.21 | – | 0.65 | 0.37 | 0.71 |
| p-value | < 0.01 | – | < 0.01 | < 0.01 | < 0.01 | |
| Vrec(tot) | Spearman coeff. | −0.19 | 0.65 | – | 0.06 | −0.01 |
| p-value | 0.01 | < 0.01 | – | |||
| VPTV | Spearman coeff. | 0.21 | 0.37 | 0.06 | – | 0.48 |
| p-value | – | |||||
| Vrec(tar)/Vrec(tot) | Spearman coeff. | 0.48 | 0.71 | −0.01 | 0.48 | – |
| p-value | < 0.01 | < 0.01 | 0.91 | < 0.01 | – |
significant results (significance level = 0.05)
Figure 2Patient distribution: Vrec(30Gy) – Vrec(tar)
Figure 3Patient distribution: Vrec(30Gy) – Vrec(tot)
Figure 4Patient distribution: Vrec(30Gy) – Vrec(tar)/Vrec(tot)
Figure 5Patient distribution: Vrec(30Gy) – VPTV
One-sample Wilcoxon test results
| Vrec(30Gy) [%] | p-value | Source | Comments | Dose [Gy]/fractions |
|---|---|---|---|---|
| 60.0 | < 0.01 | [ | IMRT | 50.4/28 |
| 65.1 | < 0.01 | [ | IMRT | – |
| 82.2 | < 0.01 | [ | HT | 50.4/28 |
| 98.4 | < 0.01 | [ | CT | |
| 97.9 | < 0.01 | [ | CT | 47.8/– |
| 94.5 | < 0.05 | [ | IMRT | 47.4/– |
| 97.7 | < 0.01 | [ | CRT | 45.0/25 |
| 97.4 | < 0.01 | [ | FIF | |
| 81.9 | < 0.01 | [ | Halcyon (node positive patients) | 45.0–55.0/25 |
| 89.7 | 0.5 | [ | HT (node positive patients) | |
| 92.4 | 0.07 | [ | Halcyon (node negative patients) | |
| 97.4 | < 0.01 | [ | HT (node negative patients) |
IMRT — intensity-modulated radiation therapy; HT — helical tomotherapy; CT — conventional therapy; CRT — conformal radiotherapy; FIF — field-in-field technique;
significant results (significance level = 0.05)
Figure 6Histogram and patient density distribution function: Vrec(tar)/Vrec(tot)
Figure 7Histogram and patient density distribution function: Vrec(30Gy)
Results of the quantile analysis — decile values
| Deciles | Vrec(30Gy) |
|---|---|
| 1 | 70.2 |
| 2 | 79.0 |
| 3 | 84.1 |
| 4 | 89.8 |
| 5 | 93.6 |
| 6 | 96.4 |
| 7 | 99.0 |
| 8 | 100.0 |
| 9 | 100.0 |